New biologic protects immunocompromised from COVID-19: studies
AstraZeneca’s long-acting monoclonal antibody can also be used to prevent disease progression, trials suggest
A novel therapy developed by AstraZeneca provides robust protection against severe COVID-19, potentially providing a prophylactic for people who fail to respond to vaccination, new data show.
The company has announced that the long-acting therapy, dubbed AZD7442, could be used for the prevention or for treatment of mild disease and could be particularly useful for severely immunocompromised patients.
